CRISPR Licensing Recent exclusive pharma licensing agreement for G-dase E(R) CRISPR-Cas technology demonstrates BRAIN Biotech's readiness to partner with biopharma firms on enzyme based gene editing platforms; target firms seeking CRISPR enabled biocatalysis and co development opportunities within BRAINBioIncubator.

Global Production Capacity With fermentation plants in the UK, continental Europe, and the USA, BRAIN Biotech can support contract manufacturing, tolling, and regional supply for specialty enzymes and microorganisms across food and life sciences, enabling rapid onboarding of new customers.

Sustainable Solutions The group's focus on customized sustainable biological solutions opens conversations with customers pursuing greener enzymes and process improvements, presenting opportunities to upsell catalyst development, process optimization, and sourcing sustainability benefits.

Growth Momentum Strong double digit sales growth in the BRAIN Biocatalysts segment signals healthy demand and a credible growth story to leverage in outreach to larger manufacturers and food producers for volume partnerships and long term contracts.

Incubator Collaborations The BRAINBioIncubator segment offers potential co development and licensing pathways with startups and pharma researchers, enabling early access to innovative enzymology and drug development platforms through joint R&D programs and milestone based partnerships.